Jiuguijiu (000799) research briefing: product structure focuses on high-end provincial markets and has potential

Jiuguijiu (000799) research briefing: product structure focuses on high-end provincial markets and has potential
Investment 武汉夜生活网 points: Product structure focuses on high-end companies. There are currently three major series of products, ultra-high-end “internal reference” series, high-end “jiujiujiu” series, and low-end “Xiangquan” series. Since the company’s production capacity is less than 1, it needs to expand production.Better time, in order to maximize the benefits, the company’s overall product structure focuses on high-end, strategically reduce sales of low-end “Xiangquan” and expand sales of ultra-high-end “internal reference” wine.As a result, the company’s premium wine (including internal reference and alcoholic liquor series) also continued to increase, from 77% in 2011 to 87% in 2018. In addition, in order to improve the company’s operating efficiency, the company reduced SKUs, highlighted strategic single products, and set up an internal reference wine sales company with a large business shareholding system.The number of SKUs started in 2018 is controlled to less than 75, which is a 25% decrease every year.The strategic single products are prominently internal reference, Red Alcoholic Alcoholic, and Alcoholic Alcoholic Heritage Edition. The resources are focused on these three products.In December 2018, the company established an internal reference wine sales company. The internal reference sales company was established by the participation of 30 large-scale large-scale distributors (most of them are Maotai and Wuliangye).By constraining the interests of large distributors, the company has enabled it, as a private enterprise, to operate the market more flexibly and promote higher growth of internal reference wine. The sustainable potential of liquor in the province’s market is the only medium-to-high-end liquor listed company in Hunan. The overall operating scale is still very small, and the company’s sales revenue in 201811.8.7 billion, of which Central China, mainly Hunan Province, has only 7.1.4 billion.The sales revenue scale of Jiuguijiu is much lower than that of Gujing Gongjiu, a medium-to-high-end real estate wine listed company in Anhui Province and Yanghe Co., Ltd., a medium-to-high-end real estate wine listed company in Jiangsu Province.Gujing Gongjiu’s income in 2018 was 86.71 ppm, of which Central China, mainly Anhui Province, earned 78.6.7 billion.Yanghe’s 2018 revenue was 231.870,000 yuan, including 116 in Jiangsu Province.1.2 billion. Undoubtedly, Jiujiu Liquor Co., Ltd. further clarified the strategy of deepening the base camp in Hunan and achieved better results.In 2018, the sales revenue of Central China with Hunan as its core increased by 39 each year.13%, accounting for 60% of the company’s total revenue.19%.The company’s full coverage of county-level market channels in Hunan Province will allow its stores to sink to the district / county level.In the future, through the in-depth cultivation strategy of the market in Hunan Province, we believe that alcoholic wine has growth potential in Hunan Province. Earnings forecast and investment rating: Maintain “Overweight” rating. Since the company established the internal reference wine sales company, increased dealer incentives, and early market expenses, we lowered the company’s profit forecast and forecasted the company’s EPS in 2019/2020/2021 respectively.Is 0.83/0.99/1.18 yuan, corresponding to PE for 2019/2020/2021 is 28.96/24.07/20.34 times.At the same time, we believe that the company is optimistic about the market development potential of the company and maintain its rating as “overweight”. Risk Warning: The product structure upgrade is not up to expectations, the market in the province is not up to expectations, the downside of the macro economy, the impact of intensified industry competition, and food safety.

BYD (002594): High growth in the first half of the year awaits heavy volume of new models

BYD (002594): High growth in the first half of the year awaits heavy volume of new models

Event Overview 2019H1 achieved revenue of 621.

800 million, an increase of 14 in ten years.

8%; net profit attributable to mother 14.

5 ppm, an increase of 203 in ten years.

6%, net profit after deducting non-return to mother 7.

40,000 yuan, an increase of 210 in ten years.


Among them, 2019Q2 revenue was 318.

80,000 yuan, an increase of 8 in ten years.

4%; net profit attributable to mother 7.

1 ppm, an increase of 87 in ten years.


After deducting non-return to mother’s net profit3.

30,000 yuan, an increase of 195 in ten years.


2019Q1-Q3 performance indicators: Expected net profit attributable to mother 15.

6 ppm-17.

6 trillion, corresponding to the growth rate of 1.

8% -14.


  Analysis and judgment: The sales of new energy vehicles have significantly increased driving revenue growth. In terms of business, 2019H1 automotive business, mobile phone foundry, and secondary battery revenue were 339.

800 million, 233.

200 million, 44.

500 million, the annual growth rate was 16.

3%, 14.

4%, -1


1) Automotive business: 2019H1 new energy vehicle revenue 254.

50,000 yuan, an increase of 38 in ten years.

8%, the 厦门夜网 proportion of revenue further increased to 40.

9%, benefiting from the high growth of the company’s new energy vehicle sales.

According to the data of China Automobile Association, the cumulative sales volume of BYD new energy vehicles in 2019H1 is 15.

730,000 vehicles, an increase of 74 in ten years.

34%, a significant increase in sales driven revenue growth.

2) Mobile phone foundry: 2017H1 and 2018H1 basically maintained a steady growth of 10% +, and continued to grow at about 4% in 2017 and 2018.

3) Secondary batteries: For the time being, it is mainly dragged down by the photovoltaic business. The domestic installed capacity of photovoltaics in 2019H1 is 11.

4 GW, a decrease of more than 50%.

  Expense control strengthened to enhance profitability 2019H1 company gross profit margin17.
1%, increase by 1 every year.
2杭州桑拿pct, mainly due to the significant increase in the gross profit margin of the automotive business.

In terms of products, the gross profit margin of the automotive business in 2019H1 was 23.

2%, an increase of 4 per year.

5pct; mobile phone foundry gross margin is 8.

6%, a decline of 3 per year.

9 points.

Net interest rate 2.

7%, increase by 1 every year.

0pct, mainly due to the strengthening of cost management and control caused the continuous decline in sales expense ratio1.

2 points to 3.

7%, the financial expense ratio fell slightly to zero in ten years.

2 points to 2.


The management expense ratio and R & D expense ratio increase slightly every year.

1pct and 0.


In a single quarter, the gross profit margin for 2019Q2 was 15.

8%, 0 per year.

4pct, net interest rate 2.

4%, a year to raise 0.

3pct, R & D expense ratio, management expense ratio, and sales expense ratio decreased by 3.

3pct, 2.

8pct, 1.


  Focus on new energy vehicle business: short-term new model-driven growth, long-term focus on increasing urban share.

  The continuously developing new energy vehicle business and the continuous development of gradual research and development. The company has achieved independent control of the technology of the new energy vehicle industry chain in power batteries and IGBTs, and has continuously improved its product line, covering both pure electric and hybrid technology routes., From the low-end to the high-end, from A00 to B, to meet a variety of consumer needs.

The company announced the sales of Xinneng Automobile in July 20191.

70,000 vehicles, down 11 every year.

8%, mainly due to subsidy decline and superimposed off-season effects.

The supplementary tax rebate caused short-term pressure on the company’s performance, but in the long run, it promotes the advantages and disadvantages of the new energy vehicle industry. The company is committed to introducing the independent controllable advantages of the new energy vehicle industry technology and the entire product line to gain more market share.

And the double-point policy relays the compensation for the downgrade to ensure the growth of the industry. Through the second half of the year, the company will launch new models such as e2, e3, the new Qin EV and e1, and a new generation of Song.High growth rate.

  Investment suggestions We believe that the company’s new energy vehicles are expected to maintain a high growth rate in 2019, and it is expected to become an independent and controllable technological advantage of core components and improve its product line to gain more market share. It is expected that revenues will increase by 15 in 2019-2020.

7% and an increase of 18.

1%, reaching 1505.

3 ppm and 1777.

500 million, net profit attributable to mothers increased by 16.

6% and an increase of 32.

8%, reaching 32.

4 ppm and 43.
0 million yuan, EPS is 1.
19 yuan and 1.

58 yuan, corresponding to 43 times and 33 times of the current PE.

With reference to the company’s historical PE interval center 35-38 times, in view of the company’s new models launched this year, the company’s PE estimate for 37 times in 2020, the target price of 58.

46 yuan, the first coverage given “overweight” rating.

  Risks suggest that the sales volume of the new energy automobile industry is lower than expected, the sales of new models are lower than expected, and the market share is lower than expected.

Pien Tze Huang (600436): The rapid growth of Pien Tze Huang sales continues to be optimistic about the company’s development

Pien Tze Huang (600436): The rapid growth of Pien Tze Huang sales continues to be optimistic about the company’s development

The event company released the 2018 annual report on April 12, the company released the 2018 annual performance report, and realized operating income in 2018. The 杭州夜生活网 net profit attributable to the parent and the net profit after deduction were 47.

6.6 billion, 11.

4.3 billion and 11.

24 ppm, an increase of 28 each year.

33%, 41.

62% and 44.

97%, realized profit 1.

89 yuan, slightly more than our navy expected.

A brief review of the company’s brand cultivation has achieved initial results. The sales of the Pianzai series have grown rapidly. In 2017, the company expanded its advertising and launched brand cultivation and promotion from TV, newspapers, high-speed rail naming rights, and today’s headlines. Major achievements at the beginning of 2018: ① Pharmaceutical industry, medicineBusiness, daily necessities and cosmetics, food and other businesses all achieved growth, with operating income of 18 respectively.

8 billion, 23.

5.4 billion, 4.

9.8 billion, 0.

1.3 billion, an increase of 28 each year.

45%, 23.

82%, 56.

71%, 3.

15%; ② Pien Tze Huang has not adjusted its price in 2018, and the growth in performance has come from the increase in sales. It can be seen that the operating income of drugs for liver disease (approximately Pien Tze Huang) has reached 17.

97 ppm, an increase of 32 in ten years.

07%, the growth rate is slightly higher than the overall growth. It can be seen that the sales of Pianzai series products have achieved rapid growth. ③ The Pianzai Experience Center covers most of the country’s capitals and major economically developed cities. It has newly entered blank provinces such as Xinjiang, Shanxi, and Inner Mongolia to promote the company.Product sales.

④ The company’s selling expenses are 3.

92 ppm, a decrease of 2 per year.

84%, promotion, business promotion, and advertising expenses have been slightly reduced, and still achieve outstanding performance. It can be seen that the company’s brand has been successfully cultivated. It is expected that the company’s brand influence will continue to promote performance growth.

Increasing investment in research and development, the Pien Tze Huang series is expected to grow for a long time. Pien Tze Huang is a national top secret formula with a long history and occupies an important position in the field of liver protection and liver protection drugs.

Based on the existing advantages, the company cultivates a large variety of Pien Tze Huang, actively develops a series of pharmacology, toxicology, quality standards and clinical research projects with the main line of treating liver diseases and tumors, and the auxiliary lines of anti-inflammatory, immune regulation, anti-alcoholic and liver protection.36.

In 2018, the company invested a total of 10.8 million yuan in research and development, an increase of 44 per year.

twenty two%.

Continuously enriching R & D projects and surplus R & D strength, the company has initially formed a R & D layout and R & D pipeline with the characteristics of the Pianzi 癀 brand, which will further enhance the company’s competitiveness and profitability, and lay the next level for the long-term sales growth of the Pianzi 癀 seriesbasis.

The strategy of “one core and two wings” is steadily advancing, and daily necessities and cosmetics first bloom. The company focuses on the development strategy of the “one core and two wings” large health industry in the field of daily necessities, cosmetics, and health food. At present, daily necessities and cosmetics have achieved rapid volume growth, and operating income in 2018 has further increased56.

71%, this part of the business mainly depends on two subsidiaries, ① Fujian Pien Tze Huang Cosmetics Co., Ltd. to achieve operating income2.

7.4 billion, an increase of 56.

95%; ②The subsidiary Zhangzhou Pianzi 癀 Shanghai Jahwa Dental Care Co., Ltd. realized operating income1.

2.2 billion, an increase of 40.


It can be seen that the company’s cosmetics and oral care businesses have successfully entered the market and won the favor of consumers. The pharmaceutical cosmetics and pharmaceutical toothpaste have precedents. This part of the company’s business promotes continuous heavy volume; therefore, the company is realizing 11 health foods and foods.The development of the company provides technical support for the strategic development of the “health products”. The company’s cosmetics and health products are expected to achieve two blossoms.

The main financial indicators were basically normal. Due to the increase in the prepayment for the subsidiary Xiamen Pianzai Honghong Pharmaceutical Co., Ltd. (consolidation), the company’s prepayment reached 1.

530,000 yuan, an increase of 39 in ten years.

4%; resettlement of the pre-paid project development and construction funds invested in 70 acres of commercial land in the previous period, and the company’s other receivables are only 40.58 million yuan, a decrease of 59.
60%; As the subsidiary Xiamen Pien Tze Huang Hongren Pharmaceutical Co., Ltd. realized the 2017 annual performance assessment profit, Fujian Yangming Kangyi Biomedical Venture Investment Enterprise paid to it 5.72 million yuan in price adjustment for intangible assets. The annual amount of 14.3 million yuan was reduced to 8.58 million yuan; the company increased direct materials for direct use of liver disease drugs, direct labor and manufacturing costs, and the main business paired reached 27.
40 ppm, gross margin is 42.

42% before 2017.

26% decreased slightly; the company reduced its publicity expenses, realized efficient management, and changes in the RMB exchange rate, so the sales expense ratio, management expense ratio and financial expense ratio were 8 respectively.

23%, 7.

17%, -0.

21%, 10 before 2017.

87%, 7.

32%, -0.

11% supplementation improved; other financial indicators of the company are basically normal.

Earnings forecast and investment rating We are optimistic that the company will enter a period of rapid growth in both volume and price: 1) Pien Tze Huang is an exclusive breed with a national top secret formula and is a resource-based Chinese medicine. In addition, the company has a long history of strong brand strength and strong pricing.Capabilities; 2) The company strives to ensure the excessive supply of raw materials for the Pien Tze Huang series in the next few years through various methods; 3) The company vigorously promotes the sales growth of the Pian Tsai Huang series through a new marketing model.

It is expected that the company’s operating income for 2019-2021 will be 61.

5.8 billion, 81.

13 ppm and 108.

6.3 billion, net profit attributable to mothers was 14.

6 billion, 19.

3.7 billion and 25.

76 trillion, an increase of 27 each year.

8%, 32.

6% and 33.

0%, equivalent to 2 respectively.

42 yuan / share, 3.

21 yuan / share and 4.

27 yuan / share, corresponding P / E is 49.

0X, 36.

9X and 27.

8x, maintain BUY rating.

Risk analysis Drug price reduction risk, accounting policy change risk, raw material supply risk and raw material price risk, exchange rate change risk.

Xingsen Technology (002436) convertible bond plan review: convertible bond fundraising and expansion will help the company advance further

Xingsen Technology (002436) convertible bond plan review: convertible bond fundraising and expansion will help the company advance further

Event: The company intends to publicly issue no more than 6 trillion convertible bonds with a term of 5 years.

On June 26, 2019, the company and the Guangzhou Economic and Technological Development Zone Management Committee signed an “Investment Cooperation Agreement”, which plans to invest a total of US $ 3 billion in the construction of semiconductor package carrier boards and similar carrier board projects.

Investment Highlights: Initial growth of convertible bonds and fund-raising expansion is foreshadowing.

The funds raised by the company’s issuance of convertible bonds will be mainly used for the automation of the IC carrier board in Guangzhou Xingsen Express Factory and the construction of the second phase of the compressed circuit board. After the project is completed, the annual production capacity will increase by 120,000 square meters and 12.

360,000 square meters.

At present, the company ‘s Guangzhou plant ‘s IC carrier boards, PCB prototypes, and small-volume boards are at a relatively high level of production capacity. Therefore, the company ‘s revenue growth rate in the first half of this year was relatively small. Through the subsidiaries of Yixing Silicon Valley, Exception and Harbor,As well as the unexpected growth of Zefeng, net profit has been improved.

However, in order to achieve stable and sustained growth, it is necessary to expand production capacity, which is the original intention of the company to raise funds.

According to the construction progress of the project, the capacity of adding IC substrates and PCB prototypes is expected to be put into production in the fourth quarter of this year to the first quarter of next year. There is also room for further release of small-volume board capacity in Yixing Silicon Valley. In the next two years, it will benefit from the acceleration of global 5G construction andThe localization of the semiconductor industry such as storage, the demand for PCB prototypes, low-volume boards, and IC substrates is different. The company’s capacity increase has been well absorbed, and it has become the main source of further growth in the next two years.

IC carrier board growth is on track, and the second main business has taken shape.

In the field of storage IC substrates, the company is currently the only domestic supplier that has passed Samsung certification in China, and the yield has reached 94%, leading the industry in terms of technology and customer reserves. 2?
In 3 years, after the production capacity of 120,000 square meters / year is completed, the company will directly import the capabilities of Samsung and other international core customers in batches.

In the IC carrier board project planned to be invested in cooperation with the Guangzhou Economic and Technological Development Zone Management Committee, the company is responsible for coordinating about 30% of the national integrated circuit industry fund investment.重庆耍耍网 According to the investment amount of the convertible bonds and the expansion of production capacity,Under the billion-dollar investment scale, it is expected that the new IC carrier board production capacity will reach 50,000-60,000 square meters per month. In addition to the existing capacity, the company’s total IC carrier board production capacity will reach nearly 80,000 square meters in the next four to five years./ Month, by then it will become the largest IC carrier board manufacturer in China.

In addition, Samsung’s supply qualification and endorsement of large funds help the company to obtain orders from internal storage customers, thereby achieving revenue and performance growth.

Earnings forecast and investment rating: Maintain Buy rating.

The company’s growth logic is gradually being realized. At present, subsidiaries such as Port, Exception and Yixing have 杭州夜网论坛 turned losses. If the capacity of IC substrates and PCB prototypes expanded by the funds raised by convertible bonds can be well absorbed, it will affect the company in the future.The two-year performance growth forms the most direct support. Based on the principle of prudence, we will not consider the impact of convertible bonds on the company’s performance for the time being. It is estimated that the net profit for 2019-2021 will be 3 respectively.

12, 4.

19 and 5.

7 billion, currently corresponding to PE 37.

18, 27.

73 and 20.

35 times.

The company is one of the few high-quality targets in the country that has both 5G and IC semiconductor attributes, and maintains the company’s buy rating.

Risk reminders: (1) IC substrate production expansion progress is less than expected; (2) PCB capacity expansion is less than expected; (3) Global 5G commercial progress is gradually expected; (4) Uncertainty in the implementation of convertible bond issuance.

Kelun Pharmaceutical (002422): Performance in line with expectations Accelerate the development of specialty preparations

Kelun Pharmaceutical (002422): Performance in line with expectations Accelerate the development of specialty preparations
Investment Highlights Event: The company released its 2019 Interim Report and H1 achieved operating income of 89.22 ppm, an increase of 14 in ten years.50%; net profit attributable to mother 7.28 ppm, a decrease of 5 per year.91%; deduct non-net profit 6.44 trillion, down 10 a year.55%. Performance was in line with expectations, and specialty preparations accelerated.In the first half of 2019, the company’s revenue grew steadily. Due to the high base of the large infusion sector last year, and the gradual benefits of Chuanning’s preferential policies and fluctuations in product prices, net profit slightly replaced. Quarterly: Q2 achieved revenue of 46.370,000 yuan (ten years +20.05% / mom + 8.08%); net profit attributable to mother 3.9.3 billion (+0.45% / + 16.95%); deduct non-net profit 3.2.6 billion (-17.53% / + 2.86%). The quarterly average quarter-on-quarter revenue increased steadily, and net profit Q2 declined slightly. Sub-segment: 1) Revenue from the infusion segment was 51.7.9 billion (+10.14%), gross margin of 70.73% (+0.68pp).Revenue increased steadily and gross profit margin increased slightly, mainly due to the steady growth in sales of soft plastics with high gross profit, the proportion increased, and the product structure continued to improve.2) Revenue from antibiotic intermediates18.1.1 billion (+10.10%), net profit 2.7.8 billion (-20.60%).Chuanning continues to be full, with stable revenue growth, but due to the termination of the reduction and exemption policy and fluctuations in intermediate product prices, net profit has improved. 3) Revenue from non-infusion preparations18.4.5 billion (+36.14%). Revenue from new specialty preparations approved since 20177.4.4 billion (+372.55%), of which the predominant variety parecoxib, parenteral nutrition series, consistency evaluation variety escital oxalate doped with pulaxr rapid volume, specialized preparations accelerate the development of power. Gross profit margin increased steadily, and R & D investment continued to increase.2019H1 company gross profit margin 59.91% (ten years +1.43pp / ring ratio +1.61pp), the structure of infusion products continued to improve, sales of specialty preparations increased, and gross profit margins increased steadily.Among the three expense ratios, the sales expense ratio is 36.33% (+3.28pp / + 2.32pp), the increase in sales expenses mainly related to the academic promotion of specialty preparations.Management expense ratio 11.26% (+1.25pp / -0.25pp), basically stable.Finance expense ratio 3.27% (-0.66pp / -0.19pp), both of which decreased slightly from the previous quarter, mainly due to the decrease in the company’s losses and the decrease in financial 南宁桑拿 indicator expenditures. During the harvest period of innovation research and development, the product was approved to accelerate.In 2018, the company has continuously approved the production of 18 important generic drugs, of which 12 new products have been approved and 6 varieties have been evaluated for consistency in generic drugs.Obtained 5 domestic clinical trial approvals for innovative drugs, submitted 1 IND application to the US FDA, and obtained clinical approval.Among them, KL-A167 enters the key clinical phase II, and KL-A166 injection is in China and the United States for phase I clinical research.In 2019, innovation and research and development have been continuously harvested, and products have been approved rapidly. It is expected that 60-80 products will be approved in the next 2-3 years, providing continuous 杭州夜网 growth momentum. Earnings forecast and estimation: We expect operating income for 2019-2021 to be 194 respectively.59, 218.77 and 243.31 ppm, an increase of 19 in ten years.00%, 12.43% and 11.22%; net profit attributable to mothers is 15 respectively.79, 20.21 and 23.0.94 million yuan, an increase of 30 in ten years.19%, 27.97% and 18.46%.Currently, the corresponding PE in 2019 is 26 times.Considering that the company is a big infusion dragon, innovation research and development is entering the harvest period. In the future, it is expected to achieve accelerated product approval and volume, grow into a domestic leader in generic drugs and innovative drugs, and maintain a “buy” rating. Risk warning events: the risk that the progress of product development approval is not up to expectations; the risk of increased competition in the large infusion industry; the environmental protection risk; the risk of changes in the price of the drug substance.

[When can I eat oatmeal to lose weight?

】 _Slimming_How to eat

[When can I eat oatmeal to lose weight?
】 _Slimming_How to eat

Now in large and small supermarkets or on the Internet, you can easily buy oatmeal to eat. Oatmeal is a food made by people using wheat. Eating oatmeal is very simple. For example, you can eat it with boiling water.It is especially suitable for the majority of professionals to buy and eat, and there are many benefits to eating oatmeal, for example, it is good for gastrointestinal health. It is worth mentioning that eating oatmeal also has the effect of losing weight.

When can I eat oatmeal to lose weight?
Oatmeal is crude fiber, and proper consumption does have the effect of conditioning the stomach and intestines, which can achieve the effect of assisting weight loss.

However, you ca n’t just rely on eating cereals to lose weight. In addition to supplementing the various nutrients mentioned above, you must also increase your exercise volume. You must exercise for half an hour to sweat your body every day without increasing your food intake.

Also, buy this kind of oatmeal, don’t buy the kind of instant oatmeal mixed with milk powder and sugar. The oatmeal did not eat much, but it absorbed too much sugar!

Be sure to buy plain cereal and mix it with low-fat milk.

Weight loss Usually people choose to eat fruits and vegetables alone, but they often have a high temperature. Do you want to eat nutrition and lose weight?

Choose oats.

Let’s first understand the nutritional value of oats.

Oats contain a lot of antioxidants, including phenolic caffeic acid, ferulic acid, coumaric acid, benzoic acid, vanillic acid, salicylic acid, syringic acid, etc., flavonoid compounds, and vitamin E, oat anthraceneAmides and more.

Many are technical terms, but salicylic acid and vitamin E should be familiar to many girls. Many whitening and anti-wrinkle cosmetics contain salicylic acid. Vitamin E is the one that has been mentioned in the Yangshengtang advertisement.It ‘s always beautiful. ”

Therefore, it is not difficult for everyone to understand that the effect of these substances is to remove free radicals, which can reduce the damage of free radicals on skin cells, reduce the appearance of wrinkles, lighten pigmentation, and maintain skin elasticity and gloss.

Even if it’s not for weight loss, beautiful girls should eat more oats.

Mistake 1: Oatmeal ≠ Oatmeal Fruit oatmeal. The main products are white sugar (syrup), dextrin, and other cereal flours. There is only a small amount of oatmeal or oatmeal in it, and there is extra oil and fruit.Dried and chopped nuts, so it tastes crispy and sweet (can’t stop at all). Take away water and make it sweeter and less sticky.

Oatmeal, especially pure oatmeal, is the one that has nothing but oats on the ingredient list, which is used to lose weight!

After cooking, the texture is sticky, the texture is smooth, hard, and you need to chew well. You will feel full in a bowl. You will not be hungry in the morning and will not be addicted to food.

Tips: Everyone must figure out this concept. Oatmeal is oatmeal, but oatmeal includes more than oatmeal.

If you want to lose weight, discard those delicious (yummy) nutritious cereals and buy pure oatmeal!

By the way, whole grain oats, eat after cooking, the effect is better!

Mistake two: eat too much and make a calculation: the mass of fruit cereals: 35g, content per 100g: 1900kJ; the content of a bowl of white rice: about 200 calories, that is, about 837kJ; the speed of 3 packets of fruit cereal:1995kJ, which is equal to rice 2.

4 bowls.

Saw it. I ate 3 bags of oatmeal every day, followed by 2.

The instant intake of 4 bowls of rice is the same (not including other snacks)!

In fact, no matter what you eat, even if you eat too much grains and vegetables with low radiation, you will gain weight.

[What is the relationship between sexual life and the four seasons]

[What is the relationship between sexual life and the four seasons]

In the relationship between husband and wife, quarrels and even divorces due to inconsistent sexual life account for a large proportion. From this perspective, using a positive attitude to face sex and better satisfy each other is a supplement to marriageAnd salvation.

So, what is the relationship between sexual life and the four seasons? Let’s take a look together: in the spring, the yang is rising, everything is flourishing, and flourishing.

At this time, the number of sexual activities is appropriately increased compared to winter, at least it is not necessary to set excessive restraint in advance.

Only in this way can the outstanding metabolic activities of the tissues and organs of each part of the body be enhanced to enhance the vitality of life.


[Five-month baby food supplement recipe]_food supplement recipe_baby_how to eat

[Five-month baby food supplement recipe]_food supplement recipe_baby_how to eat

Starting from four months, the baby has started to add complementary foods, but at this time, because the gastrointestinal function has just been fully adapted, it can not be eaten casually. Generally, you can give the baby some honey pumpkin paste or make some yolks in about five months.Porridge is for the baby, these are more nutritious, but note that if you are allergic to egg yolk, you should stop using it.

1. Honey pumpkin puree ingredients: 100 grams of pumpkin, 1 tsp of honey.

Method: Wash the pumpkin, peel it, remove the seeds and cut into slices.

Press the steamed pumpkin slices into a puree with a spoon.

Use your hands to gently mash the pumpkin into a large ball, and then put a few small balls around.

Drizzle honey before serving.

Nutrition Tips: Pumpkin or carotene can protect people’s eyes, people have bright eyes, and can also improve the overall immunity of the body.

2, egg yolk porridge ingredients: rice amount, broth (or fish soup, vegetable soup) amount, 1 egg yolk.

Method: Separate the right amount of soup with slag, such as fish soup. Be very careful to prevent fish bones.

Remove the oil from the noodle soup.

Scrambled eggs.

When cooking rice for adults, put rice and water in the pot, and use a spoon to dig a hole in the center to make the rice in the center more water. After cooking, the rice in the center will become soft rice.Mushy.

Put the soup and rice paste in the pot and cook, and use a slow heat to make a thin paste.

Then put down the egg custard, stir and boil, and place in a bowl.

You can feed your baby when the temperature is right.

Nutrition Tips: Eggs are sweet, flat, return to the spleen, stomach meridians, can nourish the lungs and nourish blood, nourish yin and moisturize, and be used for lack of qi and blood, fever and thirst.

[Is Gynostemma cold?]_ Food Properties_Hanbu Han

[Is Gynostemma cold?]_ Food Properties_Hanbu Han

Gynostemma pentaphyllum may not be seen by many people in ordinary times. Even if it is seen, it is unrecognizable. In fact, this plant can be used as a traditional Chinese medicine after a certain processing.Chinese medicinal materials are not cold and can be used to treat very many chronic diseases, such as the three high diseases. This is the most common disease people today.

This kind of medicine has the functions of anti-inflammatory and detoxification, cough and expectorant.

Gynostemma pentaphyllum is the most important and has the following characteristics of traditional Chinese medicine: use Gynostemma pentaphyllum and Ganoderma lucidum with boiled water or tea, it can treat hypertension, hyperlipidemia, hyperglycemia, mild liver embolism.

It has the effects of protecting liver and detoxifying, lowering blood pressure, and lowering blood lipids and blood sugar.

The main active ingredients of Gynostemma pentaphyllum are gypenosides, gypenosides powder (binary), tandem amino acids, flavonoids, multivitamins, trace elements, minerals, etc.

Medicinal material source: the whole grass of the gourd plant Gynostemma pentaphyllum.

Sexual taste: slightly sweet; cool.

Meridian: return to the lung; spleen; kidney.

Efficacy: Yiqi Jianpi, Huatanzhike, Qingrejiedu.

Efficacy classification: tonic medicine; phlegm remedy; heat-reducing medicine.

Indications: Deficiency, fatigue, dysfunction, leukopenia, hyperlipidemia, viral hepatitis, chronic inflammation, chronic bronchitis.

Dosage: Oral: decoction, 15-30g, ground powder, 3-6g; or make tea.

Topical: Moderate, smash and rub.

Harvesting and storage: It can be harvested 3-4 times in summer and autumn each year, washed and dried.

Contraindications: After taking the medicine, a small number of patients have symptoms such as nausea and vomiting, bloating and diarrhea (or constipation), dizziness, vertigo, tinnitus and other symptoms. If the above symptoms occur, they can be interrupted and resting.

Economic value Gynostemma pentaphylla tea has a good length for the human body. Gynostemma pentaphylla is taken from the buds and dragon whiskers of the armpit of Gynostemma pentaphyllum. The soup is clear and can be brewed continuously for 4-6 cups. The color of the soup is not reduced, and it has the nutrients contained in the growth pointThe health functions brought about by the substance are combined for a long time without any toxic or side effects.

Efficacy: Reduce blood lipids, lower blood pressure, venous thrombosis, cardiovascular disease, regulate blood sugar, promote sleep, slow aging, prevent cancer, improve immunity, and regulate human physiological functions.

Gynostemma pentaphyllum can protect the adrenal and thymus glands and endocrine organs from shrinking with age, maintain the function of the endocrine system, and have the effect of lowering blood sugar and improving glucose metabolism.

Formula: 3 grams of Gynostemma pentaphylla, brew with boiling water for 10 minutes

[How long can I get pregnant after taking the ring]_Pregnant woman

[How long can I get pregnant after taking the ring]_Pregnant woman

The birth control ring is mainly placed in the woman’s womb. Some are made of rubber and some are planned contraceptive measures.

But these can endlessly extend the endometrium together. It affects the fertilized egg. How long can it be pregnant after taking the ring? So, in daily life, we must pay attention to it.Shortened, more or less ring length will have certain damage and impact on the endometrium.

It is more than an hour of surgery. After the ring is removed, in order to improve the fertility rate, some examinations are mainly performed by men and women. The pregnancy measures, so there is a small amount of bleeding in the vagina after the ring removalAnd discomfort.

After taking the ring, in order to increase the chance of conception, check fertility conditions in detail before pregnancy, and conceive under the guidance of a doctor.

How long can a ring take to become pregnant? It must meet the following conditions: the ovaries discharge normal eggs.

The semen is normal and contains normal sperm.

Eggs and sperm can meet in the fallopian tubes and combine to become fertilized eggs.

The fertilized eggs are successfully delivered into the uterine cavity.

The endometrium is fully prepared for fertilized egg implantation.

If any of these neighbors is abnormal, it can interfere with conception.

The reason for the anti-conception may be the woman, the man, or both.

The birth control ring placed in the uterine cavity causes a sterile disease response in the endometrium, the proliferation of leukocytes and macrophages, and changes in the uterine fluid can break the ring embryo kinin, making fertilization difficult.

The contraceptive ring enters the uterus as a foreign body, which can interfere with the implantation of fertilized eggs, thereby achieving the purpose of contraception.

Not conducive to implantation of fertilized eggs, but also affect the development of the embryo sac.

And progestin-containing contraceptive rings can cause atrophy of the endometrium.

Any length of ring release, the contraceptive ring as a foreign body will have more or less damage and impact on the endometrial tissue, which will cause complications or consequences of poor growth and development, and will cause defects in the newborn. The consequences are verynot good.

Women who are wearing contraceptive rings are planning to conceive and have to wait for reconception and give the endometrium a recovery time.

The above is how long it takes to get pregnant after taking the ring. After the ring is taken, in order to improve the fertilization rate, some tests are mainly performed by men and women. The pregnancy measures, so there can be a small amount of vagina after the ring is taken in daily life.Bleeding and discomfort.
But after taking it for a week, it can disappear. At the same time, you need to wait for the pregnancy to be re-conceived, and you need to give the endometrium a time to recover.